Drug profile · INN
lidocaine
LIGNOCAINE INJECTION (BRIDGEWEST)
lidocaine (LIGNOCAINE INJECTION (BRIDGEWEST)) is a sodium channel alpha subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — lidocaine
- US status
- approved
- Class
- Nervous system (N01)
- Route
- TOPICAL
- Patents
- 2
- Programs
- 21
- Data quality
- 0.89
Quick answer
lidocaine (LIGNOCAINE INJECTION (BRIDGEWEST)) is a sodium channel alpha subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is lidocaine?
lidocaine (LIGNOCAINE INJECTION (BRIDGEWEST)) is a sodium channel alpha subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for lidocaine?
LIGNOCAINE INJECTION (BRIDGEWEST) is a marketed brand name for lidocaine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lidocaine?
lidocaine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.